Current Oncology (Aug 2024)

Oncologic and Functional Outcomes of Salvage Robot-Assisted Radical Prostatectomy: Report of the First 10 Cases

  • Takahiro Oshina,
  • Yuta Yamada,
  • Tetsuya Fujimura,
  • Satoru Taguchi,
  • Yoshiyuki Akiyama,
  • Jun Kamei,
  • Tomoyuki Kaneko,
  • Taketo Kawai,
  • Daisuke Obinata,
  • Daisuke Yamada,
  • Hiroshi Fukuhara,
  • Tohru Nakagawa,
  • Satoru Takahashi,
  • Haruki Kume

DOI
https://doi.org/10.3390/curroncol31080356
Journal volume & issue
Vol. 31, no. 8
pp. 4762 – 4768

Abstract

Read online

Background: Salvage robot-assisted radical prostatectomy (sRARP) after PSA failure in patients who underwent initial radiotherapy or focal therapy has rarely been reported in Japan. We aimed to report the oncologic and functional outcomes of the first 10 cases of sRARP. Methods: Ten patients underwent sRARP after failing to respond to initial radiotherapy or focal therapy. Initial definitive treatment included volumetric modulated arc therapy, intensity-modulated radio therapy, stereotactic body radiotherapy, heavy-ion radiotherapy, low-dose-rate brachytherapy, and high-intensity focused ultrasound. We retrospectively investigated 10 cases on oncologic and functional outcomes of sRARP. Results: The median PSA level at sRARP, amount of blood loss, and console time were 2.17 ng/mL, 100 mL, and 136 min, respectively. Positive surgical margins were found in half of the cases. Median follow-up was 1.1 years. There were no 30-day major complications. No patients had erections after sRARP. Urinary continence and biochemical recurrence (BCR) rate were 40% and 30% at 1 year after sRARP, respectively. Conclusions: Salvage RARP may be a feasible option after PSA failure in patients who underwent radiotherapy or focal therapy as initial treatment, showing acceptable BCR rate.

Keywords